57368-83-9 Usage
Molecular weight
239.74 g/mol
Structure
A derivative of tetrahydroquinoline with a chloroacetyl group attached to the 1-position and a methyl group at the 6-position.
Appearance
Likely a solid or oily liquid, depending on the conditions.
Solubility
Soluble in organic solvents such as dichloromethane, ethyl acetate, and acetone. Insoluble in water.
Stability
Stable under normal conditions, but sensitive to heat, light, and moisture.
Reactivity
Can undergo various chemical reactions such as nucleophilic substitution, elimination, and electrophilic aromatic substitution.
Applications
a. Synthesis of pharmaceuticals and agrochemicals due to its potential biological activity.
b. Building block for the synthesis of other compounds with medicinal or agricultural applications.
c. Versatile intermediate in organic chemistry.
d. Potential uses in research and industrial applications.
Safety
Handle with care, as it may be toxic or harmful. Use appropriate personal protective equipment (PPE) and follow safety guidelines when working with 1-(chloroacetyl)-6-methyl-1,2,3,4-tetrahydroquinoline.
Check Digit Verification of cas no
The CAS Registry Mumber 57368-83-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,7,3,6 and 8 respectively; the second part has 2 digits, 8 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 57368-83:
(7*5)+(6*7)+(5*3)+(4*6)+(3*8)+(2*8)+(1*3)=159
159 % 10 = 9
So 57368-83-9 is a valid CAS Registry Number.
InChI:InChI=1/C12H14ClNO/c1-9-4-5-11-10(7-9)3-2-6-14(11)12(15)8-13/h4-5,7H,2-3,6,8H2,1H3
57368-83-9Relevant academic research and scientific papers
Novel gpr120 agonists with improved pharmacokinetic profiles for the treatment of type 2 diabetes
Ji, Guoxia,Guo, Qinghua,Xue, Qidi,Kong, Ruifang,Wang, Shiben,Lei, Kang,Liu, Renmin,Wang, Xuekun
, (2021/11/27)
GPR120 is a promising target for the treatment of type 2 diabetes (T2DM), which is activated by free fatty acids (FFAs) and stimulates the release of glucagon-like peptide-1(GLP-1). GLP-1, as an incretin, can enhance glucose-dependent secretion of insulin from pancreatic beta cells and reduce blood glucose. In this study, a series of novel GPR120 agonists were designed and synthe-sized to improve the stability and hydrophilicity of the phenylpropanoic acid GPR120 agonist TUG-891. Compound 11b showed excellent GPR120 agonistic activity and pharmacokinetic properties, and could reduce the blood glucose of normal mice in a dose-dependent manner. In addition, no hypoglycemic side effects were observed even at a dose of 100 mg/kg. Moreover, 11b showed good anti-hyperglycemic effects in diet-induced obese (DIO) mice. Molecular simulation illustrated that compound 11b could enter the active site of GPR120 and interact with ARG99. Taken together, the results indicate that compound 11b might be a promising drug candidate for the treatment of T2DM.
